Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2023-08-29
- Target Recruit Count
- 30
- Registration Number
- NCT06016413
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT06008093
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 36
- Registration Number
- NCT06005324
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Qian Chu
- Target Recruit Count
- 49
- Registration Number
- NCT06001151
- Locations
- 🇨🇳
Qian Chu, Wuhan, Hubei, China
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 210
- Registration Number
- NCT05991388
- Locations
- 🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom
🇬🇧Royal Manchester Children's Hospital, Manchester, United Kingdom
🇬🇧Birmingham Children's Hospital, Birmingham, United Kingdom
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Akeso
- Target Recruit Count
- 642
- Registration Number
- NCT05990127
- Locations
- 🇨🇳
The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Cancer hospital, Chinese academy of medical sciences and Peking union medical college, Beijing, Beijing, China
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT05984277
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2023-08-09
- Target Recruit Count
- 181
- Registration Number
- NCT05983094
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 40
- Registration Number
- NCT05983276
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 170
- Registration Number
- NCT05981001
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.